Difnazole 150 mg (Fluconazole)

Adult dose

The route of administration should be determined according to the patient's clinical condition. Oral formulations are rapidly and almost completely absorbed; therefore, the doses of oral formulations (tablets, capsules, and dry syrup) and injectable formulations are the same. ○ Adults 1. Vaginal candidiasis: Administer a single 150 mg dose of fluconazole orally. 2. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive Candida infections (peritoneal, endocardial, pulmonary, urinary tract, etc.): The usual dose of this medicine is 400 mg once on the first day, followed by 200 mg once daily from the next day. The dose may be increased to 400 mg once daily according to the patient's response. The duration of treatment should be determined according to clinical response and medical judgment. 3. Cryptococcal meningitis and cryptococcosis at other sites: The usual dose of this medicine is 400 mg once on the first day, followed by 200-400 mg once daily from the next day. The duration of treatment depends on clinical and mycological response, but treatment should generally continue for at least 6 ~ 8 weeks. 4. To prevent recurrence of cryptococcal meningitis in patients with AIDS, administer 200 mg of this medicine once daily indefinitely after the patient has completed initial treatment. 5. Prevention of fungal infections in immunocompromised patients at risk due to neutropenia caused by cytotoxic chemotherapy, radiation therapy, or bone marrow transplantation: Administer 50-400 mg of this medicine once daily, depending on the patient's risk of fungal infection. A dose of 400 mg once daily is recommended for patients at very high risk of systemic fungal infection, such as those undergoing bone marrow transplantation who are expected to have severe or prolonged neutropenia. In these patients, administer 400 mg starting 5-6 days before the anticipated onset of neutropenia and continue 400 mg for 1 week after the neutrophil count has increased to 1,000 cells/mm3 or higher. 6. Onychomycosis: Administer 150 mg once weekly until the fingernail or toenail has regrown (until uninfected new nail has grown). New fingernail growth generally takes 3-6 months and toenail growth 6-12 months; the growth rate may vary by individual and age. After successful treatment with long-term use, nails may sometimes remain damaged. Dermatophyte infections of the skin, including tinea pedis, tinea corporis, tinea cruris, and cutaneous candidiasis: The usual dose is 50 mg once daily or 150 mg once weekly for 2-4 weeks. However, treatment of tinea pedis may be required for 6 weeks depending on the course. For tinea versicolor, administer 50 mg once daily for 2-4 weeks. ○ Older adults Use the usual adult dose if renal function is normal. In patients with renal impairment (creatinine clearance 50 mL/min or less), reduce the dose or extend the dosing interval. ○ Patients with renal impairment This medicine is excreted mainly in the urine unchanged. No dose adjustment is needed for a single dose; however, when multiple doses are required, administer the usual dose only on the first day and adjust the dose from the following day as follows: Creatinine clearance (mL/min) > 50: 100% of the usual dose Creatinine clearance (mL/min) ≤50 (not on dialysis): 50% of the usual dose Patients on hemodialysis: 100% of the usual dose after each hemodialysis session Patients on hemodialysis should receive 100% of the usual dose after each hemodialysis session. On non-dialysis days, administer a reduced dose according to creatinine clearance.

This medication should not be used in certain patients. For example, it should not be taken by individuals allergic to this medication or similar drugs, pregnant women or those who may become pregnant, and nursing mothers. Furthermore, patients currently taking certain medications may also need to avoid using this medication together. For example, there may be a risk to the heart when used with some medications such as terfenadine, cisapride, astemizole, and erythromycin. This medication contains lactose, so it should not be administered to patients with lactose intolerance or specific metabolic disorders. Patients with impaired kidney or liver function, those with heart disease, or those at risk for arrhythmias due to electrolyte abnormalities should use this medication with caution and their condition should be periodically monitored during treatment. This medication may affect liver function, so it is recommended to undergo blood tests, liver function tests, and kidney function tests before and during treatment. While taking this medication, rare side effects such as skin rash, liver damage, blood abnormalities, arrhythmias may occur; if any abnormal symptoms appear, the healthcare provider should be informed immediately. Additionally, this medication can interact with various other drugs, so all current medications should be disclosed to the healthcare provider, and care should be taken if combined. Pregnant or nursing women should avoid taking this medication, and women of childbearing age must ensure effective contraception during and for a certain period after treatment. For children, especially infants under 6 months of age, the safety and efficacy of this medication have not been established, hence it should be used cautiously when necessary. Driving or operating machinery may cause dizziness or seizures due to this medication, so caution is necessary. Finally, in case of overdose, hallucinations or altered behavior may occur, so the dosage should be strictly adhered to, and immediate contact with a healthcare facility should be made in case of excessive intake.

Agranulocytosis, leukopenia, neutropenia, thrombocytopenia, anaphylaxis, angioedema, hypertriglyceridemia, hypercholesterolemia, hypokalemia, insomnia, drowsiness, headache, seizures, dizziness, paresthesia, taste abnormalities, tremors, vertigo, Torsades de Pointes, QT prolongation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, bloating, dry mouth, increased ALT, increased AST, increased serum alkaline phosphatase, cholestasis, jaundice, increased bilirubin, hepatotoxicity, liver failure, hepatocellular necrosis, hepatitis, hepatocyte damage, rash, itching, urticaria, increased sweating, drug rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, facial edema, hair loss, drug reaction with eosinophilia and systemic symptoms, myalgia, fatigue, lethargy, weakness, fever, adrenal insufficiency, hallucinations, disorganized behavior

This medication must be stored in a tightly closed container to keep air and moisture out. Moreover, it is important to store it at a temperature between 1°C and 30°C. This will help maintain the medication's effectiveness.

Appearance

Pink rectangular tablet

Package unit

30 tablets/bottle